CRBP
Price
$7.40
Change
-$0.62 (-7.73%)
Updated
Jun 27 closing price
Capitalization
91.65M
STOK
Price
$11.63
Change
-$0.21 (-1.77%)
Updated
Jun 27 closing price
Capitalization
634.42M
44 days until earnings call
Interact to see
Advertisement

CRBP vs STOK

Header iconCRBP vs STOK Comparison
Open Charts CRBP vs STOKBanner chart's image
Corbus Pharmaceuticals Holdings
Price$7.40
Change-$0.62 (-7.73%)
Volume$1.39M
Capitalization91.65M
Stoke Therapeutics
Price$11.63
Change-$0.21 (-1.77%)
Volume$1.37M
Capitalization634.42M
CRBP vs STOK Comparison Chart in %
Loading...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRBP vs. STOK commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBP is a Hold and STOK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (CRBP: $7.49 vs. STOK: $11.62)
Brand notoriety: CRBP and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBP: 754% vs. STOK: 192%
Market capitalization -- CRBP: $91.65M vs. STOK: $634.42M
CRBP [@Biotechnology] is valued at $91.65M. STOK’s [@Biotechnology] market capitalization is $634.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBP’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • CRBP’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than CRBP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBP’s TA Score shows that 3 TA indicator(s) are bullish while STOK’s TA Score has 2 bullish TA indicator(s).

  • CRBP’s TA Score: 3 bullish, 6 bearish.
  • STOK’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, CRBP is a better buy in the short-term than STOK.

Price Growth

CRBP (@Biotechnology) experienced а -9.10% price change this week, while STOK (@Biotechnology) price change was +0.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

CRBP is expected to report earnings on May 06, 2025.

STOK is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($634M) has a higher market cap than CRBP($91.7M). STOK YTD gains are higher at: 5.349 vs. CRBP (-36.525). STOK has higher annual earnings (EBITDA): 40.3M vs. CRBP (-48.74M). STOK has more cash in the bank: 357M vs. CRBP (133M). STOK has less debt than CRBP: STOK (2.35M) vs CRBP (2.86M). STOK has higher revenues than CRBP: STOK (191M) vs CRBP (0).
CRBPSTOKCRBP / STOK
Capitalization91.7M634M14%
EBITDA-48.74M40.3M-121%
Gain YTD-36.5255.349-683%
P/E RatioN/A14.17-
Revenue0191M-
Total Cash133M357M37%
Total Debt2.86M2.35M121%
FUNDAMENTALS RATINGS
CRBP vs STOK: Fundamental Ratings
CRBP
STOK
OUTLOOK RATING
1..100
5776
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9641
PRICE GROWTH RATING
1..100
5938
P/E GROWTH RATING
1..100
10031
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRBP's Valuation (51) in the Biotechnology industry is in the same range as STOK (53) in the null industry. This means that CRBP’s stock grew similarly to STOK’s over the last 12 months.

CRBP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as STOK (100) in the null industry. This means that CRBP’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (41) in the null industry is somewhat better than the same rating for CRBP (96) in the Biotechnology industry. This means that STOK’s stock grew somewhat faster than CRBP’s over the last 12 months.

STOK's Price Growth Rating (38) in the null industry is in the same range as CRBP (59) in the Biotechnology industry. This means that STOK’s stock grew similarly to CRBP’s over the last 12 months.

STOK's P/E Growth Rating (31) in the null industry is significantly better than the same rating for CRBP (100) in the Biotechnology industry. This means that STOK’s stock grew significantly faster than CRBP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRBPSTOK
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 11 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PBLCX42.76N/A
N/A
Principal Blue Chip C
SDVGX16.52N/A
N/A
Sit Dividend Growth I
AVUDX7.98N/A
N/A
American Century Value R6
QMGYX12.65N/A
N/A
Invesco Advantage International Y
TQSIX23.14N/A
N/A
T. Rowe Price Integrated US SMCC Eq I

CRBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRBP has been loosely correlated with SKYE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBP jumps, then SKYE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRBP
1D Price
Change %
CRBP100%
-6.61%
SKYE - CRBP
47%
Loosely correlated
-2.33%
FBIO - CRBP
39%
Loosely correlated
-2.16%
STOK - CRBP
37%
Loosely correlated
-1.86%
APLS - CRBP
34%
Loosely correlated
-5.27%
PMCB - CRBP
30%
Poorly correlated
-2.86%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with IMNM. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
-1.86%
IMNM - STOK
52%
Loosely correlated
-0.11%
NRIX - STOK
52%
Loosely correlated
+0.26%
IDYA - STOK
52%
Loosely correlated
-4.04%
RNA - STOK
50%
Loosely correlated
-2.68%
QTTB - STOK
49%
Loosely correlated
-5.16%
More